Danny’s has a strong background in preclinical animal models of psychiatric disorders including addiction, anxiety, and obsessive-compulsive disorder. He has expertise in neuroanatomy, behavioral pharmacology, cell signaling, mouse genetics, immunohistochemistry, and fluorescent imaging. Danny believes that psychiatric diseases, especially the ones that are difficult to treat with conventional pharmacotherapies, are circuit-based disorders that require both experiential and neurochemical interventions. This is why he is so passionate about the potential of psychedelic-assisted psychiatry to transform the way we treat mental illness. Danny aims to help elucidate the mechanisms by which rapidly-acting antidepressants and psychoplastogens can facilitate meaningful improvements in treatment outcomes for people with refractory psychiatric diseases.
Psychedelic drugs like LSD powerfully alter consciousness and promote neural plasticity, but drug tolerance occurs rapidly following the first dose. Although the mechanisms that underlie psychedelic tolerance may overlap with those that confer a therapeutic effect, until recently these mechanisms were unknown.